These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15959603)

  • 21. Treatment of recurrent hepatitis C.
    Gane E
    Liver Transpl; 2002 Oct; 8(10 Suppl 1):S28-37. PubMed ID: 12362295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
    Neumann U; Puhl G; Bahra M; Berg T; Langrehr JM; Neuhaus R; Neuhaus P
    Transplantation; 2006 Jul; 82(1):43-7. PubMed ID: 16861940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Childs-Kean LM; Hand EO
    Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients].
    Rocca P; Bailly F; Chevallier M; Chevallier P; Zoulim F; Trépo C
    Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):294-9. PubMed ID: 12700516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
    Davis GL; Wong JB; McHutchison JG; Manns MP; Harvey J; Albrecht J
    Hepatology; 2003 Sep; 38(3):645-52. PubMed ID: 12939591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M
    N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract]   [Full Text] [Related]  

  • 29. [An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C].
    Zhang HF; Yang XJ; Zhu SS; Dong Y; Chen DW; Jia WZ; Xu ZQ; Mao YL; Tang HM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Jun; 19(2):185-7. PubMed ID: 16027794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 31. Peginterferon and ribavirin for hepatitis C.
    Duggan AE; Duggan JM
    N Engl J Med; 2007 Mar; 356(12):1269; author reply 1271. PubMed ID: 17377169
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
    Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
    Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration?
    Wright TL
    Liver Transpl; 2003 Nov; 9(11):S109-13. PubMed ID: 14586905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of acute hepatitis C with PEG-interferon and ribavirin].
    Nicolas I; Pons JA
    Gastroenterol Hepatol; 2003 Apr; 26(4):275-6. PubMed ID: 12681125
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatitis C: FDA public meeting on peginterferon plus ribavirin, Nov. 14.
    AIDS Treat News; 2002 Oct; (384):5. PubMed ID: 12434764
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatitis C virus infection.
    Bacon BR; Di Bisceglie AM
    N Engl J Med; 2001 Nov; 345(19):1425-6; author reply 1427-8. PubMed ID: 11794183
    [No Abstract]   [Full Text] [Related]  

  • 38. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
    Malnick SD; Basevitch A
    Gastroenterology; 2006 Aug; 131(2):683; author reply 683-4. PubMed ID: 16890628
    [No Abstract]   [Full Text] [Related]  

  • 39. Chronic hepatitis C.
    Mohsen A; Norris S
    Clin Evid; 2005 Dec; (14):920-30. PubMed ID: 16620443
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatitis C (chronic).
    Mohsen A; Norris S
    Clin Evid; 2006 Jun; (15):1061-72. PubMed ID: 16973044
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.